Mammary Cell News Volume 14.46 | Dec 15 2022

    0
    54








    2022-12-15 | MCN 14.47


    Mammary Cell News by STEMCELL Technologies
    Vol. 14.47 – 15 December, 2022
    TOP STORY

    Phosphoproteomic Analysis of Neoadjuvant Breast Cancer Suggests That Increased Sensitivity to Paclitaxel Is Driven by CDK4 and Filamin A

    Researchers conducted a phosphoproteomic screening of samples from HER2-negative female breast cancer receiving neoadjuvant paclitaxel, aiming to find candidate biomarkers of paclitaxel sensitivity.
    [Nature Communications]

    Full Article
    Explore Antibodies for Epithelial Cell Markers
    PUBLICATIONSRanked by the impact factor of the journal

    Exosomal miR-1304-3p Promotes Breast Cancer Progression in African Americans by Activating Cancer-Associated Adipocytes

    Scientists identified miR-1304-3p as the most upregulated microRNA in African American patients. Importantly, its expression significantly correlated with poor progression-free survival in African American patients.
    [Nature Communications]

    Full Article

    Breast Cancer Cells Survive Chemotherapy by Activating Targetable Immune-Modulatory Programs Characterized by PD-L1 or CD80

    Investigators showed that breast tumors surviving chemotherapy activate complex programs of immune modulation. Characterization of residual disease revealed distinct tumor cell populations.
    [Nature Cancer]

    Abstract

    NARF Is a Hypoxia-Induced Coactivator for OCT4-Mediated Breast Cancer Stem Cell Specification

    Researchers identified nuclear prelamin A recognition factor (NARF) as a hypoxia-inducible, hypoxia-inducible factor 1 target gene in human breast cancer cells.
    [Science Advances]

    Full Article

    Unconventional Isoquinoline-Based SERMs Elicit Fulvestrant-Like Transcriptional Programs in ER+ Breast Cancer Cells

    To improve the understanding of ERα structure-transcriptional relationships, scientists developed a series of chemically unconventional antagonists based on the antiestrogens elacestrant and lasofoxifene.
    [npj Breast Cancer]

    Full Article

    AKTIP Loss Is Enriched in ERα-Positive Breast Cancer for Tumorigenesis and Confers Endocrine Resistance

    The authors identified that loss of AKTIP, which is located on 16q12.2, drove tumorigenesis of estrogen receptor alpha (ERα)-positive, but not ERα-negative, breast cancer cells and was associated with poor prognosis of patients with ERα-positive breast cancer.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Zearalenone and Its Metabolite Exposure Direct Estrogen Metabolism towards Potentially Carcinogenic Metabolites in Human Breast Cancer MCF-7 Cells

    The effects of zearalenone and its metabolites α-zearalenol and β-zearalenol on the formation of carcinogenic estrogen-catechols in MCF-7 cells were investigated.
    [Mycotoxin Research]

    Abstract

    Adipocytes Secretome from Normal and Tumor Breast Favor Breast Cancer Invasion by Metabolic Reprogramming

    Adipose stem cells were differentiated into adipocytes, and the subsequent adipocyte conditioned media were evaluated for their fatty acid profile, adipokine secretion, and influence on proliferation, migration, and invasion on tumoral and normal human breast cell lines.
    [Clinical and Translational Oncology]

    Abstract

    DUSP28 Promotes Cell Proliferation, Migration, and Invasion by Akt/β-Catenin/Slug Axis in Breast Cancer

    Dual-specificity phosphatase 28 (DUSP28) level was identified by qRT-PCR and western blot assays. The proliferation, migration, and invasion of DUSP28 in MCF-7 and MDA-MB-231 cells were assessed by Cell Counting kit-8, colony formation, and transwell assays.
    [Acta Biochimica Polonica]

    Abstract
    ON777CS-HowtoOrganize_728x90
    REVIEWS

    Re-Evaluation of the Myoepithelial Cells Roles in the Breast Cancer Progression

    The authors address the roles delivered by myoepithelial cells (MECs) in breast cancer progression and decipher the molecular mechanisms regulating proper MECs’ physiology, integrity, and terminal differentiation.
    [Cancer Cell International]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

    Biomerica, Inc. received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the UAE Ministry of Health and Prevention for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device.
    [Biomerica, Inc.]

    Press Release
    FEATURED EVENT

    ESMO Breast Cancer 2023

    May 11 – 13, 2023
    Berlin, Germany

    > See All Events

    JOB OPPORTUNITIES

    Higher Scientific Officer – Cancer Dynamics

    Institute of Cancer Research – London, England, United Kingdom

    Staff Scientist – Research Pathology Group

    Institute of Cancer Research – London, England, United Kingdom

    Postdoctoral Positions – Ovarian and Breast Cancer Models

    UC Davis School of Medicine – Davis, California, United States

    Clinical Development Medical Director – Oncology & Hematology

    Novartis – East Hanover, New Jersey, United States

    Postdoctoral Position – Maternal Immune System

    Case Western Reserve University – Cleveland, Ohio, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter